Yahoo
NYSE - Nasdaq Real Time Price USD

West Pharmaceutical Services, Inc. (WST)

410.53 -6.14 (-1.47%)
As of 1:08:11 PM EDT. Market Open.
Trade WST on Coinbase
WST Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for WST

What's happening with WST?

10m ago
Powered by Yahoo Scout

West Pharmaceutical Services delivered a strong Q3 2026 earnings beat, led by High-Value Product demand, margin expansion, and GLP-1-related growth. Management raised full-year guidance, while West Vantage weakness, SmartDose divestiture effects, valuation concerns, and the stock’s 1.51% current regular-session decline on October 30remain key investor considerations.

Powered by Yahoo Scout
  • Previous Close 416.67
  • Open 419.06
  • Bid 410.52 x 10000
  • Ask 411.64 x 20000
  • Day's Range 407.67 - 422.08
  • 52 Week Range 223.83 - 438.27
  • Volume 405,082
  • Avg. Volume 571,737
  • Market Cap (intraday) 28.645B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 52.56
  • EPS (TTM) 7.81
  • Earnings Date Oct 29, 2026
  • Forward Dividend & Yield 1.04 (0.25%)
  • 1y Target Est 442.20
  • Morningstar Rating Rating available with Stock Picks access

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

www.westpharma.com

10,800

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

WST
49.55%
S&P 500 (^GSPC)
10.69%

1-Year Return

WST
47.85%
S&P 500 (^GSPC)
11.06%

3-Year Return

WST
29.45%
S&P 500 (^GSPC)
81.84%

5-Year Return

WST
3.24%
S&P 500 (^GSPC)
64.53%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 874.5M
Earnings 214M
Profit Margin 24.47%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
200M
400M
600M
800M
18.0%
20.0%
22.0%
24.0%

Analyst Insights

View More

Analyst Price Targets

340.00 Low
442.20 Average
410.53 Current
500.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/30/2026
Analyst Barclays
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 440 -> 500

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.81%

  • Return on Assets (ttm)

    12.77%

  • Return on Equity (ttm)

    21.23%

  • Revenue (ttm)

    3.4B

  • Net Income Avi to Common (ttm)

    638.9M

  • Diluted EPS (ttm)

    7.81

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    464.1M

  • Total Debt/Equity (mrq)

    10.28%

  • Levered Free Cash Flow (ttm)

    326.94M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: